Lynk Pharma Starts US Trials of Triple-Kinase Inhibitor for Myelofibrosis

Hangzhou Lynk Pharma has started a US Phase I trial of its novel triple-kinase inhibitor in patients with myelofibrosis. The trial will enroll patients with primary myelofibrosis (PMF) and secondary myelofibrosis (PV/ET-MF) induced by polycythemia vera or primary thrombocytosis. LNK01002 targets three kinase drivers of PMF and PV/ET-MF with the potential to treat patients who are not responsive or have developed resistance to conventional therapies. Founded in 2018, Lynk discovers and develops innovative drugs to treat cancer, as well as immune and inflammatory diseases. More details.... Share this with colleagues: // //